Chart - you can draw at the chart
Starting Amount
$
After
years
Dividend yield
%
Dividends reinvested
$
Strata Skin Sciences, Inc.
Type
Public
Traded as NASDAQ: MELA
Headquarters Irvington, New York, United States
Website melasciences.com

MELA Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations. The company’s flagship product, MelaFind®, is intended to be used when a trained dermatologist chooses to obtain additional information to help decide whether to biopsy certain clinically atypical pigmented skin lesions. The FDA has approved MELA Sciences’ MelaFind® pre-market approval application for use in the United States. Following completion of a successful conformity assessment procedure, MELA Sciences has also been granted CE Mark approval for sale of MelaFind® in the European Union.

In July 2015, the company acquired PhotoMedex Inc. and is planning to relocate its headquarters from Irvington, New York to Horsham, Pennsylvania in Montgomery County.

If caught early, melanoma can be cured.

Melanoma is the deadliest form of skin cancer, responsible for about 75% of skin cancer fatalities, according to the Skin Cancer Foundation.

There are an estimated 135,000 new cases of melanoma diagnosed in the U.S. every year.

Every hour, one person in the U.S. dies of melanoma and 15 people are diagnosed with the disease, according to the American Cancer Society.

What causes melanoma?

Melanoma is frequently caused by exposure to the sun, which triggers the uncontrolled growth of skin pigment cells or melanocytes. On the surface of the skin, melanoma can look like other irregular, harmless moles. However, beneath the surface there may be a peculiar cellular growth pattern.

Anyone can get melanoma, though it is more prevalent in certain parts of the country and among Caucasians. Dermatologists are especially concerned because melanoma is the most common cancer in people aged 25–29 and the second most common cancer in teens and young adults aged 15–29.

Investment goal date:
Dividends reinvested
Strata Skin Sciences, Inc. MELA report Q3 2015
Period
Date
Adjusted Actuals EPS
GAAP EPS
Q1 2016
2016-05-09
--
--
Q4 2015
2016-03-30
--
--
Q3 2015
2015-11-12
-1.2900
-1.2900
Q2 2015
2015-08-13
-0.9700
-0.9700
Q1 2015
2015-05-14
-1.1200
-1.1200
Q4 2014
2015-03-30
-1.1400
-1.0900
Q3 2014
2014-11-12
-0.4400
-0.4400
Q2 2014
2014-08-13
0.0000
0.1000
Q1 2014
2014-05-13
0.0000
-1.6000
Q4 2013
2014-03-17
0.0000
-0.9000
There is presents forecasts or rating agencies and recommendation for investors about this ticker
Funds
Fund Name
Ticker shares
ACADIAN ASSET MANAGEMENT LLC
5694
Bank of New York Mellon Corp
13455
BlackRock Fund Advisors
4790
BlackRock Inc.
329025
BlackRock Institutional Trust Company, N.A.
322637
Broadfin Capital, LLC
961422
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM
22570
CITIGROUP INC
4730
GOLDMAN SACHS GROUP INC
19018
GUGGENHEIM CAPITAL LLC
15265
NORTHERN TRUST CORP
11378
RENAISSANCE TECHNOLOGIES LLC
138800
SABBY MANAGEMENT, LLC
708021
Vanguard Group, Inc
57577
WEDBUSH MORGAN SECURITIES INC
18110
Major Shareholders
Name Relationship
Total Shares
Holding stocks
DIMUN ANTHONY J
1.9400% (101013)
MELA /
BRAGINSKY SIDNEY
0.2900% (15000)
MELA /
ODONNELL JEFFREY F
0.2600% (13513)
ESMC / MELA /
Cook Robert W.
0.1900% (10000)
CRMD / IMNP / MELA /
MEADS MINDY C
0.1000% (5070)
MELA / NILE / WTSL /
STONE DAVID K
0.4500% (23514)
MELA /
STEWART MICHAEL R
1.9200% (100000)
MELA / PHMD /
Steinhart Richard I
0.4800% (25000)
ATOS / MELA / TGTX /
Castleman Breaux
2.2500% (117238)
ISIS / MELA / USMD /
Cleary Martin D
0.7800% (40443)
MELA /
Lufkin Dan W
8.9600% (467115)
MELA /
Wagner Gerald D
0.9000% (46962)
MELA /
Chryssis George C
0.9800% (51000)
MELA /
Gulfo Joseph V
3.9900% (208311)
MELA /
Kabelev Nikolai
0.0900% (4761)
MELA /
Via LuAnn
0.5500% (28513)
CBK / MELA /
Crane Rosemary A
1.3000% (67570)
MELA /
Egger Anne M
0.3100% (16350)
MELA /
Coradini Robert
2.6700% (139024)
MELA /
Broadfin Healthcare Master Fund Ltd
19.3400% (1008297)
Goddard John Geoffrey
0.1900% (10000)
MELA /
% ()